Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

| ALNYLAM PHA Form 4 June 06, 2014 | ARMACEU | TICALS, I | INC. | | | | | | |
|--|--|-----------|---|---|--|--|--|---|--|
| June 06, 2014 FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). (Print or Type Responses) | | | | | | | | OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5 | |
| 1. Name and Address of Reporting Person <u>*</u> CLARKE JOHN K | | | 2. Issuer Name and Ticker or Trading Symbol ALNYLAM PHARMACEUTICALS, INC. [ALNY] | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner | | | | |
| · · · · · · | (Last) (First) (Middle) 00 THIRD STREET | | | of Earliest Tran Day/Year) 2014 | isaction | Officer (giv below) | below) | ner (specify | |
| | | | | Filed(Month/Day/Year) Applicable Line) _X_ Form filed by C | | | Dint/Group Filing(Check One Reporting Person More than One Reporting | | |
| (City) (S | State) | (Zip) | Tab | le I - Non-Dei | rivative Securities | Acquired, Disposed of | of, or Beneficia | ally Owned | |
| | unsaction Date th/Day/Year) | | Date, if | TransactionA Code D | Securities cquired (A) or isposed of (D) nstr. 3, 4 and 5) (A) or mount (D) Price | Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| Reminder: Report on | · | | | | Persons who re information cor required to resp displays a curre number. | r or indirectly. espond to the colle ntained in this form cond unless the for ently valid OMB co r Beneficially Owned | i are not rm ntrol | SEC 1474 (9-02) | |

- Derivative Securities Acquired, Disposed of, or Beneficial (*e.g.*, puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. Number of | 6. Date Exercisable and | 7. Title and Amount of |
|-------------|------------|---------------------|--------------------|----------|---------------|-------------------------|------------------------|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transact | iorDerivative | Expiration Date | Underlying Securities |

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

| Security (Instr. 3) | or Exercise Price of Derivative Security | | any (Month/Day/Year) | Code (Instr. 8) | Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | (Month/Day/Year) f | | (Instr. 3 and 4) | |
|--------------------------------------|---|------------|-------------------------|--------------------|--|-----------------------|--------------------|------------------|-------------------------------------|
| | | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (right to buy) | \$ 59.25 | 06/05/2014 | | A | 15,000 | 06/05/2015 | 06/04/2024 | Common Stock | 15,000 |

Reporting Owners

| Reporting Owner Name / Address | | Relationsh | | | | | |
|--|----------|------------|---------|-------|--|--|--|
| | Director | 10% Owner | Officer | Other | | | |
| CLARKE JOHN K 300 THIRD STREET CAMBRIDGE, MA 02142 | Х | | | | | | |
| Signatures | | | | | | | |
| By: /s/ Michael P. Mason, Atto Clarke | | 06/06/2014 | | | | | |
| <u>**</u> Signature of Rep | | Date | | | | | |

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.